logo
KYAN Technologies to Present New Data on Optim.AI™ Immunotherapy and Real-World Pan-Cancer Utility at AACR 2025

KYAN Technologies to Present New Data on Optim.AI™ Immunotherapy and Real-World Pan-Cancer Utility at AACR 2025

Data shows validation of FPM platform in breast cancer immunotherapy and 85% clinical concordance across over 20 solid cancers and hematologic malignancies.
SINGAPORE, SINGAPORE, SINGAPORE, April 19, 2025 / EINPresswire.com / -- KYAN Technologies Pte. Ltd. ('KYAN') today announced that two abstracts will be presented on its Optim.AI™ functional precision medicine platform at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25 – 30, in Chicago, Illinois.
The two studies highlight the clinical utility and translational potential of Optim.AI™, a platform that rapidly identifies effective treatment combinations through ex vivo functional screening and combinatorial analytics, supporting both personalized patient care and oncology drug development.
BREAST CANCER IMMUNOTHERAPY: FUNCTIONAL COMBINATORIAL EVALUATION
In this study, KYAN researchers applied an experimental adaptation of the Optim.AI™ platform to evaluate immunotherapy combinations in breast cancer. The approach integrated high-content imaging, short-term 3D tumor-immune co-culture, and combinatorial analysis to rank the effectiveness of immunotherapy combinations in HER2-positive and triple-negative breast cancer spheroids co-cultured with peripheral blood mononuclear cells (PBMCs). The platform enabled real-time assessment of immune cell infiltration and tumor-specific killing, allowing for the phenotypic ranking of all possible combinations of from12 FDA-approved therapies, including ADCC/CDC antibodies and antibody-drug conjugates (ADCs).
'This study bridges a key gap in immunotherapy testing,' said Sharon Pei Yi Chan, Scientist at KYAN Technologies. 'By integrating multi-cellular, high-content screening with the Optim.AI™ platform, we're able to evaluate immunotherapy-based combinations in clinically relevant tumor models, using limited material and within a rapid timeframe. This creates a new path for functional, patient-specific immuno-oncology strategies.'
REAL-WORLD CONCORDANCE: MULTI-CANCER CLINICAL VALIDATION
A second study evaluated 75 retrospective and prospective clinical cases across more than 20 cancer types to assess the real-world concordance of Optim.AI™ with patient treatment outcomes. The platform demonstrated 85.4% concordance with actual clinical responses, accurately identifying both effective and resistant regimens. Cancer types included non-Hodgkin lymphoma, acute myeloid leukemia, sarcoma, breast, colorectal and ovarian cancers, amongst others, with sample sources such as bone marrow, peripheral blood, tissue biopsies, and pleural effusions. These results reinforce the platform's ability to distinguish treatments associated with clinical benefit from those unlikely to be effective, underscoring its clinical application across a diverse set of patient cases.
'These results validate the ability of Optim.AI™ to support therapeutic decision-making by accurately predicting both response and resistance,' said Dr. Edward Kai-Hua Chow, Chief Scientific Officer at KYAN Technologies. 'By functionally interrogating hundreds of treatment permutations using patient-derived samples, we can deliver clinically meaningful insights within days, helping clinicians make more informed and timely therapy choices.'
'We're bridging the cancer care gap by advancing revolutionary technologies that are clinically validated and built for real-world use,' said Hugo Saavedra, CEO of KYAN Technologies. 'Optim.AI™ is uniquely positioned to transform drug development and how treatment decisions are made by combining speed, precision, and wide applicability in a way traditional approaches simply can't. These new studies show how Optim.AI™ can help drug developers and clinicians uncover new and effective treatment options, whether through cutting-edge immunotherapy testing or pan-cancer functional precision medicine.'
Details on presentations are below:
Abstract Control Number: 4450
Title: Real-world concordance analysis of a combinatorial functional precision medicine platform, Optim.AI™, in both solid and hematological cancers
Session Title: Targeted Therapies and Combinations 4
Session Start Time: 4/30/2025 9:00:00 AM
Session End Time: 4/30/2025 12:00:00 PM
Location: Poster Section 35
Poster Board Number: 20
Presentation Number: 7214
Abstract Control Number: 4534
Title: Application of Optim.AI™ platform for predictive evaluation of immunotherapy combinations in breast cancer
Session Title: Drug Discovery Assay Technologies
Session Start Time: 4/29/2025 2:00:00 PM
Session End Time: 4/29/2025 5:00:00 PM
Location: Poster Section 16
Poster Board Number: 20
Presentation Number: 5492
ABOUT KYAN TECHNOLOGIES
KYAN Technologies is a functional precision medicine company advancing a platform for rapid, combination-focused cancer treatment insights. Its proprietary platform, Optim.AI™, uses experimentally derived data from patient tumor samples or preclinical models to identify effective drug combinations across a broad therapeutic search space.
KYAN's early work in combination therapy optimization revealed insights that led to the development of a scalable phenotypic screening approach designed to assess actual treatment response. Built on a clinically validated, evidence-based foundation, Optim.AI™ has demonstrated predictive accuracy across diverse cancer types and now informs both personalized oncology care and translational research, bringing clinically grounded understanding earlier into the drug development process.
KYAN is headquartered in Singapore and is expanding U.S. operations through a collaboration with Mayo Clinic Laboratories to support CLIA validation and scale drug development partnerships. The company will also participate in the AACR Oncology Industry Partnering Event to advance strategic collaborations with pharma and biotech innovators.
For media inquiries contact:
Sudha Sruthi, Corporate Development
email us here
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FDA Issues Highest Risk Warning For Cheeseburger Recall
FDA Issues Highest Risk Warning For Cheeseburger Recall

Newsweek

time6 hours ago

  • Newsweek

FDA Issues Highest Risk Warning For Cheeseburger Recall

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A brand of cheeseburgers is being recalled due to undeclared allergens. Sheehan Brothers Vending issued a voluntary recall for its Cheeseburgers, which were distributed across three states, due to undeclared sesame. As a result, the Food and Drug Administration (FDA) has classified the recall as a Class I health risk, the most serious type of recall. Why It Matters According to the FDA, millions of people in the U.S. have food allergies or food sensitivities. Food sensitivities can range from mild reactions to potentially life-threatening symptoms. The agency recognizes nine major food allergens: milk, eggs, sesame, fish, tree nuts, crustacean shellfish, peanuts, wheat and soybeans. File photo dated 09/07/14 of a generic stock photo of a pile of cheeseburgers and french fries. File photo dated 09/07/14 of a generic stock photo of a pile of cheeseburgers and french fries. Press Association/AP What To Know As well as the cheeseburgers, the company is also recalling its Spicy Chicken Sandwich, Italian Mini Subs, Pepperoni Pizza Sub, Chili Cheese Coney and BBQ Riblet with coleslaw due to undeclared sesame. All the products have been issued a Class I health risk. A Class I health risk, as defined by the FDA, is issued when there is a reasonable probability that the use of or exposure to a product will cause serious adverse health consequences or death. This designation signals that the product poses an immediate danger to public health and requires urgent attention from both consumers and health professionals. The affected products were distributed in Indiana, Kentucky, and Ohio, specifically through Micro Markets and vending machines located throughout all of Ohio, northern Kentucky, and eastern Indiana. They were available for purchase between July 2 and July 8, 2025. The issue was identified during a routine inspection conducted by the Ohio Department of Agriculture. While no illnesses have been reported in connection with the recalled items, individuals with a sesame allergy or severe sensitivity are at risk of experiencing a serious or potentially life-threatening allergic reaction if they consume the product. All the affected products were wrapped in plastic. What People Are Saying The FDA, in an email to Newsweek in January: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall, the FDA shares that release on our website as a public service. "The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall." It added: "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled." What Happens Next Consumers who have a sesame allergy or sensitivity are advised to dispose of the affected product immediately and contact Sheehan Brothers Vending to receive a replacement pack. Anyone experiencing signs or symptoms of a foodborne illness or allergic reaction should seek medical attention promptly.

The under-the-radar injections people are taking to build muscle this summer — including the 'Wolverine' shot
The under-the-radar injections people are taking to build muscle this summer — including the 'Wolverine' shot

Business Insider

time11 hours ago

  • Business Insider

The under-the-radar injections people are taking to build muscle this summer — including the 'Wolverine' shot

Peptide injections are soaring in popularity for fitness and longevity. They're marketed as a "natural" supplement for muscle-building, fat loss, recovery, and more. The FDA has been cracking down on peptide sellers, and experts say some caution is warranted. People who want to feel younger, look fitter, or perhaps slough off a little layer of belly fat have been turning to an increasingly popular kind of treatment — one you can get without a prescription. They've got obscure names like BPC-157, tesamorelin, and cerebrolysin. All it takes is a tiny needle and a little clear vial filled with injectable molecules. Welcome to the world of peptides. "Absolutely everybody's asking for it, the field is popping," Dr. Florence Comite, a longevity doctor who serves concierge medicine clients in New York City, told Business Insider. The peptide landscape is so large that it almost defies definition. The prescription drugs Ozempic and Mounjaro, often used for weight loss, are peptides. So is insulin. There are peptides in skin creams, hair products, and high-end serums marketed to women to reduce fine lines and stimulate collagen. The wildly popular fitness supplement creatine? Also a peptide. Then, there are the gym bro shots, said to boost muscle, burn fat, stimulate testosterone, and aid recovery. Demand for peptide injections — something that biohackers and longevity-seekers have already been quietly using in the shadows for decades — is booming. Patients in pockets of the country saturated with peptides, like Beverly Hills, San Diego, Silicon Valley, and Manhattan are increasingly asking their doctors: "should I try peptides?" Many physicians aren't sure what to say because there isn't a ton of great evidence around about how much peptides can really do. Plus, the FDA has been cracking down on peptide compounders in recent years. They worry that the hype is outpacing good evidence. How peptides boost your body Unlike most pills that doctors prescribe, peptides live in a more slippery area, between drug and bodily substance. A peptide is a chain of organic compounds — specifically, amino acids — that stimulate natural processes. Depending on which amino acids a peptide is made of, and how it is used, the molecule can have all kinds of impacts on how our hormones operate. Peptides can improve fertility in both men and women, tamp down inflammation, remove dangerous visceral belly fat, or help build muscle. Others are thought to help improve sleep quality, even possibly improve brain health. "What's great about peptides is that they mimic the body," said Comite, who has been working with peptides since she was a research fellow at the National Institutes of Health over 30 years ago. Since most peptides are too fragile to be formulated as pills, they are often packaged as a clear liquid in a little vial. Users learn to inject their peptides using a very fine, short needle, right at home. The popularity of peptides has soared on their reputation as ostensibly "natural" products. The idea being that, unlike other drugs or steroids, peptides are a safer choice because they're just stimulating your body to do its own thing. Taking growth hormones, for example, comes with a suite of undesirable potential side effects, like an increased risk of cancer and type 2 diabetes. What if you could just take a peptide that would stimulate your own growth hormone to make you stronger, leaner, and more energetic? "The theory is that even if you use a growth hormone stimulating peptide, your body's only going to be able to make so much growth hormone," Dr. Sajad Zalzala, a longevity physician and one of the cofounders of AgelessRx, said. "Kind of like a check valve already in place. Again, that's the theory." The peptides gym bros take to get chiseled muscles One darling peptide of gym bros and longevity fiends alike is a substance called BPC-157. It's known as the "Wolverine" shot for its perceived ability to heal you up and regenerate your body real fast like the Marvel character, Logan, after a big fight. B-P-C stands for "body protection compound." BPC-157 was first derived from stomach juices. It's being investigated to treat inflammatory bowel diseases, including Crohn's and ulcerative colitis. But the reason that athletes like it is because it's thought to reduce inflammation and improve blood flow — and perhaps do even more. There are a few other super popular peptides: Tesamorelin, an injectable peptide, is prescribed to HIV patients to reduce excess belly fat. Sermorelin is supposed to help with sleep and recovery. CJC-1295 binds to growth hormone receptors in the body, and people often take it alongside impamorelin, which stimulates the hypothalamus. The two in tandem are said to deliver better muscle gains. On Reddit and YouTube people share how they "stack" different peptides like this, taking multiple different kinds with the goal of boosting the effects of each. Peptide fans get their shots at clinics and med spas — or, for less money, online. Increasingly, people are ordering peptides that are labeled "for research only," meaning they are supposed to be used by lab workers for experimentation, and were never meant to be put into human bodies. That's partly because the FDA crackdown on peptides has intensified in recent years, just as pharmaceutical compounding (a sort of acceptable way to get knock off medications) has surged in popularity, with people seeking cheaper versions of GLP-1 drugs like Ozempic and Mounjaro. At the beginning of 2022, the FDA had a list of four peptides that they said "may present significant safety risks" and should not be compounded. By the end of 2023, there were 26. Comite thinks the FDA crackdown is a shame. She is finding it harder and harder to source compounded liquid BPC-157. She often uses a patch form of BPC-157 on herself, placing it over sore areas or injuries. Recently, she tore a calf muscle, so she's been using it there, but she also just likes how taking a little bit of it keeps her active and moving. "I use it almost every day," she said. "It's amazing for joints and everything — at a very tiny dose." Zalzala, who doesn't usually prescribe peptides, ordered some topical BPC-157 recently when his wife had a knee injury. "My wife says it works," he said, though he cautioned that it's hard to really know if that's true without more proper research. Bracken Darrell, the CEO of VF Corporation and one of Comite's patients, is also a BPC-157 convert. A self-proclaimed "basketball nut," he's on the court about three days a week. On the days when he doesn't pick up a ball, he's out cross-training on a bike or lifting weights. So when he tore his meniscus about four months ago, he was worried. Under Comite's supervision, he started taking liquid BPC-157 about three to four times a week. He told BI it was "weird" at first, learning to inject the needle into an area of skin near his knee. But, pretty soon, it was just part of his routine. "I believe it helped a lot, but it's hard to know for sure," he said. "There are people with a severely torn meniscus who don't ever play basketball again, and I'm back — I certainly wouldn't conclude that's because I'm taking BPC-157, but at a minimum it didn't hurt. And it sure seems like it helps." Proceed with caution, doctors say Even longevity doctors who prescribe and use peptides regularly agree that some folks are overdoing it, and that could be dangerous. "Proceed with caution, because you have to know the source and you have to know it's active," Comite said. "It's not like Lowe's or Home Depot where you can get stuff and you can fix the plumbing." In reality, the evidence for peptides is still murky. There are no big, randomized clinical trials like what we have for prescription drugs or vaccines. The current hype is based on anecdotal evidence, a few small human studies from decades ago, and rodent studies. "People wanna take the peptides because they're not from big pharma, they're not mainstream medicine, they gotta be better than those cockamamie doctors," Dr. Eric Topol, a cardiologist and longevity expert, said recently on the Dax Shepard podcast. "Where's the data?" For people who are using peptides, experts shared two pieces of advice: Comite urges patients to start slow. A common mistake people who are dosing themselves make is thinking that "if a little bit is good, then a lot must be better," she said. That's not the case. "Taking mega doses of tesmorelin along with testosterone causes your organs to overgrow," Comite said. Sometimes she'll see a toned gymgoer with a potbelly, and wonder whether that's due to an enlarged liver or spleen. Darrell recommends testing your peptides with an independent lab so you know what you're getting is both real and uncontaminated. Zalzala says his company started thinking about offering peptides a few years back, due to consumer demand, but they haven't yet. There are just so many peptides out there, and it's hard to tell which might be the very best. Some of the most research-backed ways to have an impact on your longevity and fitness are still the simplest anyway: eat decent amounts of fiber and protein regularly, work out — at least a couple sessions with weights each week, and cut back (or ideally, eliminate) liquid sugar in your diet like juice and soda.

New Mexico Pinon Coffee recalls pods due to contamination risk
New Mexico Pinon Coffee recalls pods due to contamination risk

New York Post

time13 hours ago

  • New York Post

New Mexico Pinon Coffee recalls pods due to contamination risk

A New Mexico coffee company is recalling its single-serve cups due to contamination concerns. The company, New Mexico Pinon Coffee, said it is voluntarily recalling one lot of its New Mexico Pinon Coffee Dark Pinon Single Serve Cups in a 10-count box. Advertisement The single-serve cups are filled with ground coffee flavored with natural flavorings. The affected batch is about 154 Dark Pinon 10ct Single Serve cups. The Food and Drug Administration (FDA) described the issue, saying the clear coat seal on the lid of the single-serve cups did not get applied consistently to all cups in the production run and could cause food coloring to run into the cup during brewing. The company didn't receive any reports of illnesses or injuries associated with the product. Advertisement Still, the company said it is recalling the product out of an abundance of caution. The product was sold on Amazon, according to its website. No other New Mexico Pinon Coffee products have been impacted by the recall. Consumers that have purchased these products are asked to either throw away or return the product for a refund. Advertisement New Mexico Pinon Coffee voluntarily recalled one lot of its New Mexico Pinon Coffee Dark Pinon Single Serve Cups in a 10-count box. REUTERS The company recalled the product out of an abundance of caution. New Mexico Pinon Coffee / Facebook 'At New Mexico Piñon Coffee, quality means everything to us,' the company told FOX Business in a statement. 'While the issue was isolated and poses no health risk, it didn't meet the standard of excellence you've come to expect from us.' Advertisement The company said it has already addressed the issue and taken steps to refine its process moving forward. The recall has been deemed a Class III, which is when situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences, according to the FDA.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store